News | March 18, 2009

Cryosurgery Outcomes Similar to Radiotherapy in Localized Prostate Cancer

Advanced Rradiation Centers

March 18, 2009 - Cryosurgery produces clinical outcomes similar to those from external beam radiation therapy in localized prostate cancer at three years, but may be more beneficial with longer follow-up, according to a study sponsored by the Alberta Cancer Board and the National Cancer Institute of Canada.

Cryosurgery is a minimally invasive therapy that involves inserting probes into the prostate to generate subzero temperatures and induce apoptosis and secondary necrosis in cancerous cells. Short-term results and quality-of-life data have been comparable with those of other treatment modalities, but long-term effectiveness is not fully known.

The current study randomized 244 men in a 1:1 ratio to cryosurgery or external beam radiation therapy (EBRT), with a median follow-up of 100 months (range, 65-128 months). In all, 231 men received treatment.

Seven of 91 men (7.7 percent) treated with cryosurgery were biopsy positive for recurrence at 36 months, compared with 22 of 76 (29 percent) treated with radiotherapy.

It is not exactly clear why cryosurgery may produce better outcomes over time, said Bryan J. Donnelly, M.D., a urologist with the Tom Baker Cancer Centre in Calgary, Canada.

"It may be that there are some residual cells left in the prostate after radiation, whereas cryotherapy is more ablative up front," he said. "Another possibility, and there is increasing evidence, is that cryotherapy induces a cryoimmune response."

The panel also noted that gland size is a factor; the larger the gland, the more difficult it is to attain a uniformly low temperature. A prior history of transurethral resection of the prostate is a relative contraindication for cryosurgery. High-risk patients may require multimodal therapy.

The study excluded patients with bulky T3 disease or a PSA greater than 20 ng/mL. Two-thirds of patients had a Gleason score of 7 or higher, as staged by biopsy. Their mean age was 69 years. The first third of patients in the radiotherapy arm received 68 Gy before the dose was increased to 73.5 Gy. Neoadjuvant hormone therapy was extended from 3 to 6 months.

The definition of biochemical failure used in clinical trials changed three times during the study period, and low accrual resulted in the trial's being underpowered. Nine patients were lost to follow-up, 10 died from prostate cancer, and 23 died from other causes.

Using 14 different evaluation tools, there was no significant difference in quality of life between the two arms, said Dr. Donnelly at the meeting, which was sponsored by the American Society of Clinical Oncology, the American Society for Therapeutic Radiology and Oncology, and the Society of Urologic Oncology. At 36 months, 29.1 percent of men in the cryotherapy arm and 29.8 percent of men in the radiotherapy arm reported having sexual intercourse in the previous two months, although more men in the cryosurgery arm required aids.


For more information:

Related Content

New Prostate Cancer Radiotherapy Technique Aims to Preserve Sexual Function
News | Radiation Therapy | June 18, 2018
A multicenter clinical trial being led by UT Southwestern physicians is testing a technique for sparing nerve bundles...
Elekta Unity High-Field MR-Linac Receives CE Mark
News | Image Guided Radiation Therapy (IGRT) | June 18, 2018
Elekta announced that its Elekta Unity magnetic resonance radiation therapy (MR/RT) system has received CE mark,...
Washington University in St. Louis Begins Clinical Treatments With ViewRay MRIdian Linac
News | Image Guided Radiation Therapy (IGRT) | June 14, 2018
June 14, 2018 — The Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in S
Accuray TomoTherapy System Beneficial in Two Total Body Irradiation Studies
News | Radiation Therapy | June 13, 2018
Recently published data from two new studies demonstrate the benefits of Accuray’s TomoTherapy System in the delivery...
IsoRay Funding Brain Cancer Treatment Research With Ochsner Clinic Foundation
News | Brachytherapy Systems | June 12, 2018
IsoRay Inc. announced the initiation of research funding for brain cancer treatment to Ochsner Clinic Foundation, a not...
News | Brachytherapy Systems | June 07, 2018
IsoRay Inc. announced the upcoming release of its Build-Blu delivery system for real-time prostate brachytherapy.
Raysearch RayStation
Feature | Radiation Therapy | June 05, 2018 | By Melinda Taschetta-Millane
Treatment planning systems are at the heart of r...
Beaumont Researchers Invent New Mode of Proton Treatment for Lung Cancer
News | Proton Therapy | May 31, 2018
Members of Beaumont Health’s proton therapy team presented research on a new treatment for patients with lung cancer at...
More Than 60 Percent of Patients Seeking Proton Therapy Initially Denied Coverage
News | Proton Therapy | May 25, 2018
The Alliance for Proton Therapy Access has released a national report revealing the heavy emotional and financial...
News | Treatment Planning | May 24, 2018
Daniela Schmitt, Ph.D., took top honors in the overall category of the 2018 TROG Plan Study: Stereotactic Radiosurgery...
Overlay Init